Drug Puts A $750,000 'Price Tag On Life'
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.
Read more on NPR
August 2, 2017 at 12:05AM
Health Care
Thứ Tư, 2 tháng 8, 2017
Đăng ký:
Đăng Nhận xét (Atom)
0 nhận xét:
Đăng nhận xét